Hypothesis

Melatonin signaling during the dark phase directly suppresses the NAD‑consuming enzyme CD38, thereby creating a nightly NAD+ surge that powers SIRT1‑dependent repair pathways. When this melatonin‑CD38 gate is disrupted, NAD+ levels fall, SIRT1 activity wanes, and circadian‑driven protection against aging hallmarks is lost.

Mechanistic Basis

The suprachiasmatic nucleus drives melatonin release from the pineal gland at night. Melatonin binds MT1 receptors on peripheral cells, activating Gi‑protein pathways that reduce cAMP and inhibit transcription of Cd38. Lower CD38 activity means less NAD+ is cleaved to ADP‑ribose, preserving the NAD+ pool for SIRT1 deacetylation of BMAL1, CLOCK, and downstream targets such as PGC‑1α and FOXO factors. This creates a feedback loop: SIRT1 deacetylates and stabilizes BMAL1, reinforcing circadian amplitude, while robust clock drives melatonin synthesis. Consequently, darkness is not merely a permissive state for melatonin; it actively gates NAD+ availability through CD38 suppression.

Predictions & Tests

1. Nighttime NAD+ levels will be significantly higher than daytime levels in wild‑type mice, and this difference will disappear in mice lacking MT1 receptors or treated with the MT1 antagonist luzindole.
2. Cd38 mRNA and protein expression will show an inverse rhythm to melatonin, peaking during the light phase and being repressed at night; this repression will be lost in MT1‑knockout animals.
3. SIRT1 activity, measured by deacetylation of known substrates (e.g., p53, PGC‑1α), will follow the NAD+ rhythm and be blunted when CD38 is pharmacologically overexpressed or when melatonin signaling is blocked.
4. Chronic disruption of the melatonin‑CD38 axis (e.g., constant light exposure or luzindole treatment) will accelerate age‑related phenotypes—reduced mitochondrial respiration, increased ROS, and shortened lifespan—whereas nightly NAD+ supplementation will rescue these effects only when melatonin signaling is intact.

Potential Challenges

Competing NAD+ consumers such as PARPs and sirtuins other than SIRT1 may mask the impact of CD38 changes; it's important to include PARP inhibition to isolate the CD38‑SIRT1 axis. Additionally, melatonin’s antioxidant actions could independently affect NAD+ turnover; we're better off using MT1‑selective ligands to disentangle receptor‑mediated effects from direct radical scavenging.

This hypothesis makes the circadian clock’s anti‑aging power concrete: darkness‑driven melatonin imposes a nightly NAD+ gate that fuels SIRT1‑mediated repair, positioning timed melatonin or CD38 inhibition as a targetable geroprotective strategy.